In a randomized controlled trial in patients with newly diagnosed T1D who received either GAD-Alum vaccination or subcutaneous placebo (alum alone) was no difference in fasting c-peptide concentrations or insulin requirements after 15 months [66]. Here, GAD1 is linked to type 1 diabetes mellitus.